{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:regenold-gmbh-q140571087-answer-4591d5048634f515fd4b","key":"buyer_question:regenold-gmbh-q140571087-answer-4591d5048634f515fd4b","kind":"buyer_question","slug":"regenold-gmbh-q140571087-answer-4591d5048634f515fd4b","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/regenold-gmbh-q140571087-answer-4591d5048634f515fd4b","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/regenold-gmbh-q140571087-answer-4591d5048634f515fd4b.json","datePublished":"2026-10-26","dateModified":"2026-10-26","materialFingerprint":"fnv1a64:4751682e567f095c","membershipFingerprint":"fnv1a64:ebfa9a6744ac32d8","relatedEntitySlugs":["regenold-gmbh-q140571087"],"relatedSurfaceKeys":["buyer_question:regenold-gmbh-q140571087-answer-37a711685e2365c3a89f","buyer_question:regenold-gmbh-q140571087-answer-37f1dca73a0e057e757e","buyer_question:regenold-gmbh-q140571087-answer-498842324866f417c390","buyer_question:regenold-gmbh-q140571087-answer-4b02d27790070848d2d9","buyer_question:regenold-gmbh-q140571087-answer-4ee5241047a65dad957c","buyer_question:regenold-gmbh-q140571087-answer-518e5a634038e207425b","buyer_question:regenold-gmbh-q140571087-answer-58e1a9f02c93d9d42247","buyer_question:regenold-gmbh-q140571087-answer-6d349f787f5c4fa379d6","buyer_question:regenold-gmbh-q140571087-answer-9aed178f2fe661510ed2","buyer_question:regenold-gmbh-q140571087-answer-9eae8d071e1ec8a20afa","buyer_question:regenold-gmbh-q140571087-answer-a226a9a6037046c1549a","buyer_question:regenold-gmbh-q140571087-answer-ad0e76bb92db40823d71","buyer_question:regenold-gmbh-q140571087-answer-ddcfce807ca92b72ecfd","buyer_question:regenold-gmbh-q140571087-answer-e1389031ab82135145ac","buyer_question:regenold-gmbh-q140571087-answer-ec6f98f6761598e4f43e","buyer_question:regenold-gmbh-q140571087-answer-f284b044f7926ab6dbda","buyer_question:regenold-gmbh-q140571087-answer-f34785f5ae19196605b7","evidence:regenold-gmbh-q140571087"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"regenold-gmbh-q140571087-content-616544846ed4eda7-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q140571087","sourceRevisionId":"Q140571087:content:42d5154a2e8358d1","sourceContentHash":"fnv1a64:88817713b3e21398","recordRevisionId":"Q140571087:content:42d5154a2e8358d1","recordContentHash":"fnv1a64:03e35b32ff7e009f","sourceCanonicalUrl":"https://regenold.com/","sourceModifiedAt":"2026-10-26T12:36:16.052Z","observedOn":"2026-10-26","permission":{"basis":"public_information","evidenceUrl":"https://regenold.com/"},"attributionUrl":"https://regenold.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"How does the EU HTA Regulation affect my market access strategy?","summary":"Cited source answers across 1 active corpus record.","question":"How does the EU HTA Regulation affect my market access strategy?","answers":[{"entitySlug":"regenold-gmbh-q140571087","entityName":"regenold GmbH","answer":"“The EU HTA Regulation introduced Joint Clinical Assessments (JCAs) that produce EU-wide clinical evidence evaluations. Since January 2025, JCAs apply to new oncology products and ATMPs.”","sourceUrls":["https://regenold.com/services/market-access-and-hta-strategy"]}]}